Immunomonitoring results of a pivotal phase II/III study with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with malignant ascitesM. Jaeger, A. Schoberth,M. Hennig,A. Burges,M. Heiss,P. Wimberger,B. Schmalfeldt,H. LindhoferONKOLOGIE(2010)引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要